STOCK TITAN

CFO at Bio-Techne (TECH) exercises 62,000 options and settles taxes in shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-TECHNE Corp CFO James Hippel reported compensation-related equity activity. On May 5, 2026, he exercised 62,000 shares of stock options into common stock at an exercise price of $47.60 per share, converting a derivative award into direct share ownership.

On the same date, 56,955 shares of common stock were disposed of in a tax-withholding transaction at $56.68 per share, covering exercise price or tax obligations rather than representing an open-market sale. Following the exercise, his direct common stock holdings were 210,625 shares, and after tax withholding they were 153,670 shares, while he retained a substantial portfolio of unexercised options and restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Hippel James
Role CFO
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) 62,000 $0.00 --
Exercise Common Stock 62,000 $47.60 $2.95M
Tax Withholding Common Stock 56,955 $56.68 $3.23M
holding Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Performance Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Restricted Stock Units -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
Holdings After Transaction: Stock Options (Right to Buy) — 62,068 shares (Direct, null); Common Stock — 210,625 shares (Direct, null); Performance Restricted Stock Units — 13,865 shares (Direct, null); Performance Stock Options (Right to Buy) — 37,314 shares (Direct, null); Restricted Stock Units — 4,010 shares (Direct, null)
Footnotes (1)
  1. Fully exercisable. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Options exercised 62,000 shares Stock options converted to common stock on May 5, 2026
Option exercise price $47.60 per share Exercise price for 62,000 options
Shares used for tax/exercise 56,955 shares Common stock delivered at $56.68 to cover tax or exercise costs
Tax-withholding price $56.68 per share Price for code F disposition of 56,955 common shares
Shares after exercise 210,625 shares Direct common stock holdings after option exercise
Shares after tax withholding 153,670 shares Direct common stock holdings after code F disposition
Largest remaining option block 167,328 shares at $66.97 Unexercised stock options expiring August 5, 2027
Restricted Stock Units financial
"security_title": "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"security_title": "Performance Restricted Stock Units""
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Performance Stock Options (Right to Buy) financial
"security_title": "Performance Stock Options (Right to Buy)""
tax-withholding disposition financial
"transaction_action": "tax-withholding disposition""
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
exercise price financial
"conversion_or_exercise_price": "47.6000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hippel James

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026M62,000A$47.6210,625D
Common Stock05/05/2026F56,955D$56.68153,670D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$47.605/05/2026M62,000 (1)08/07/2026Common Stock62,000$062,068D
Stock Options (Right to Buy)$66.97 (1)08/05/2027Common Stock167,328167,328D
Stock Options (Right to Buy)$120.46 (1)08/06/2028Common Stock40,53640,536D
Stock Options (Right to Buy)$94.52 (3)08/15/2029Common Stock45,22045,220D
Performance Restricted Stock Units(2) (4) (4)Common Stock13,86513,865D
Performance Stock Options (Right to Buy)$84.61 (4)08/15/2030Common Stock37,31437,314D
Stock Options (Right to Buy)$84.61 (5)08/15/2030Common Stock45,92345,923D
Performance Restricted Stock Units(2) (6) (6)Common Stock24,06224,062D
Restricted Stock Units(2) (7) (7)Common Stock4,0108,021D
Stock Options (Right to Buy)$74.91 (8)08/15/2034Common Stock32,41732,417D
Restricted Stock Units(2) (9) (9)Common Stock23,08923,089D
Performance Restricted Stock Units(2) (10) (10)Common Stock29,42029,420D
Restricted Stock Units(2) (11) (11)Common Stock14,71014,710D
Stock Options (Right to Buy)$53.6 (12)08/15/2035Common Stock37,63237,632D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BIO-TECHNE Corp (TECH) CFO James Hippel report on this Form 4?

James Hippel reported an option exercise and related tax withholding. He exercised 62,000 stock options at $47.60 per share and 56,955 shares of common stock were withheld at $56.68 per share to cover exercise price or tax obligations, changing his direct shareholdings.

How many BIO-TECHNE (TECH) stock options did the CFO exercise and at what price?

The CFO exercised 62,000 stock options at $47.60 per share. These options converted into 62,000 shares of common stock on May 5, 2026, reflecting the use of a previously granted equity award rather than an open-market purchase of new shares.

Were any BIO-TECHNE Corp (TECH) shares sold on the open market in this Form 4?

The filing shows no open-market sales by the CFO. The only disposition is a Form 4 code F transaction, where 56,955 shares of common stock were delivered at $56.68 per share to pay the option exercise price or satisfy tax liabilities.

What are James Hippel’s BIO-TECHNE (TECH) common stock holdings after these transactions?

After the option exercise, Hippel directly held 210,625 common shares. Following the tax-withholding disposition of 56,955 shares, his direct holdings were 153,670 shares, according to the totals reported in the Form 4 for the non-derivative common stock transactions.

What derivative awards and RSUs does the BIO-TECHNE (TECH) CFO still hold?

The CFO retains multiple option and restricted stock unit awards. Remaining positions include stock options on 167,328 shares at a $66.97 exercise price, additional options at higher prices, and various restricted and performance restricted stock units tied to future vesting and performance conditions.